Under a tenth of individuals that would benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it releases its initial guidance on the therapies.
With over a billion individuals worldwide currently living with obesity, it is calling for increased and just access to GLP-1 medication.
Based on projections, more than two billion could be obese by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a long-term condition that can be treated with thorough and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to broad availability to the injections that can assist patients in reducing considerable body mass, says the organization.
Skinny Jab Scarcity
Despite the present most optimistic outlook, the supply of GLP-1 therapies could only cover about 100 million people – fewer than 10% of those who need them, per the health organization.
The guideline urges nations and manufacturers to widen access, by strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Operate
The injections replicate a body's own hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so people reduce food intake.
Patients commonly start to lose weight after several weeks of beginning the regular doses.
Research points to patients may put most of the weight back on a year later of halting the treatment, when their usual hunger come back.
To be carrying excess weight raises your likelihood for developing diseases, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight concerns people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
